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Macular Corneal Dystrophy (MCD) is a rare autosomal recessive disorder 
affecting the stroma of cornea. Most cases of MCD are caused by mutations 
in CHST6 gene. The aim of this study was to determine mutations in the 
carbohydrate sulfotransferase 6 gene (CHST6) through genetic analysis of 7 
Iranian patients with MCD.
Materials & Methods 
We screened the CHST6 gene to determine the range of pathogenic mutations. 
Genomic DNA was extracted from peripheral blood leukocytes. The coding 
regions of the CHST6 gene were amplified using three pairs of primers, and 
directly sequenced in the final step. 
Results 
Four mutations were found to affect the translated protein and each of them 
corresponded to a particular disease haplotype that has been previously 
reported. 
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Introduction
Corneal dystrophies are a heterogeneous group of disorders that may lead to severe 
visual impairment (1). Macular Corneal Dystrophy (MCD) is an autosomal recessive 
disorder that is clinically characterized by progressive corneal stroma haze in both 
eyes (1, 2). Initially, patients have diffuse, fine superficial clouding in the corneal 
stroma. In the course of time, the opacities extend through the entire thickness of 
the cornea and involve the central and surrounding cornea. The involved corneal 
stroma is often thinner than normal (3). The prevalence of MCD varies immensely 
in different parts of the world but the condition is rare in most populations. In some 
countries, MCD accounts for 10-75% of corneal dystrophies which require corneal 
grafting (4).
MCD is divided into three immunophenotypes (MCD types I, IA, and II) based 
on the reactivity of the patient’s serum and corneal tissue to an antibody that 
recognizes sulphated keratan sulfate (KS). However, these subtypes are clinically 
indistinguishable from each other (5-7). By identifying the locus of MCD on 
chromosome 16 (8) and fine mapping the gene (9, 10), mutations in the carbohydrate 
sulfotransferase gene (CHST6) encoding corneal N-acetylglucosamine-6-0-
sulfotransferase (C-GlcNAc-6-ST) were identified as the cause of MCD types I and 
II (11). While mutations of the coding region of CHST6 were found in MCD types I, 
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IA , and II (12-14), DNA rearrangements in the upstream 
region of CHST6 that could influence gene regulatory 
elements affecting transcription of CHST6 have been 
reported in MCD type II. The aim of this study was to 
screen CHST6 mutations in 7 Iranian patients from 
apparently unrelated families diagnosed with MCD.
Materials & Methods
Seven individuals with MCD from unrelated Iranian 
families, as well as 20 age-matched healthy control 
subjects, were included in this study. The age of the 
patients varied between 15 and 50 years of age with 
a mean of 28 years. An informed written consent was 
obtained from each participant for clinical and molecular 
genetic studies. Patients were referred by corneal 
specialists from Farabi Eye Hospital. On slit lamp 
examination, all patients had typical signs of the disease 
as characterized by whitish, nodular lesions or spots in 
the superficial stroma. In some patients, progression of 
disease was noted as the coalescence of the multiple 
spots into larger nodules and a diffuse stromal opacity 
including the peripheral cornea. Most patients had lost 
full vision and need penetrating keratoplasty. Loss of 
vision and photophobia were common signs among the 
patients. In 7 patients who had undergone penetrating 
keratoplasty, diagnosis was confirmed by histopathologic 
examination. 
Examination of the pedigree of all patients confirmed the 
autosomal recessive pattern of the inheritance. None of 
the patients had raised intraocular pressure or posterior 
segment abnormalities.
For mutation analysis, peripheral blood (5 ml) was 
collected from each patient and genomic DNA was 
extracted by using the Diatom DNA extraction Kit (gene 
Fanavaran, Tehran, Iran). The CHST6 gene is 126.9 kb 
in length and consists of 4 exons, of which only exon 4 
contains the coding sequence of 1,189 bp. Three pairs of 
primers were used to amplify the entire coding region of 
CHST6 as described previously (13). PCR products were 
purified by the Qia quick PCR purification kit (Qiagen, 
Valencia, CA) and directly sequenced on both strands. 
Sequencing was carried out in an automatic fluorescent 
DNA sequencer ABI 3700 ( Macrogene, Korea), and the 
resulted data were compared with the published cDNA 
sequence of CHST6 by Clustal-X software (version 
1.8). The nucleotide +1 is the first nucleotide of the 
CHST6 cDNA sequence (GenBank accession number 
AF2119990). For the enumeration of the amino acids, the 
codon for the initiator methionine, starting at nucleotide 
693 of the CHST6 cDNA, is numbered as codon 1.
Results
All patients received penetrating keratoplasty (PK) 
before or after DNA sampling. Corneal buttons were 
stained with alcian blue and hematoxylin-eosin and the 
MCD diagnosis was confirmed histologically. Screening 
results showed 4 different mutations (table 1). 
Different mutations have been reported in MCD patients 
(11-22). These 4 mutations have also been reported in 
previous studies: H249R (15) P31L (20), R127C (15) 
and D203Y (11). This study confirmed the findings of 
another study which evaluated these mutations in Iran 
(23). 
Our data regarding the CHST6 gene among 7 Iranian 
patients confirmed that present mutations in this gene 
were causative of MCD. We suggest the screening of 
these mutations in Iranian patient. 
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Nucleotide change Type of change Amino acid change
A 3 1438A>G† Homozygous H249R
B 2 784C>T† Homozygous P31L
C 1 1071C>T† Homozygous R127C
H 1 1299G>T† Heterozygous  D203Y
† Reported mutations: H249R (15) P31L (20), R127C (15) and D203Y (11)
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Discussion 
Macular Corneal Dystrophy (MCD), a disease affecting 
the stroma of cornea, usually becomes symptomatic 
in the first decade of life. In this disease, fuzziness 
is developed in the cornea and the attacks of pain 
progress into the later years of the patient’s life. MCD 
is an autosomal recessive disease caused by abnormal 
configuration of keratin sulfate. Most cases of MCD are 
caused by mutations in CHST6 gene. The mutations 
reported in this study seem to be prevalent in Iran. By 
screening all the exons of the gene, new mutations might 
be discovered (23).
In this study, Sequencing analysis revealed four missense 
mutations (p.D203Y, R127C, p.P31Land p.H249R)  of 
CHST6 in the Iranian patients with MCD. The p.R127C 
mutation is located between the 5’-PSB and the 3’-
PB domain. The p.D203Y mutation is located in the 
RX7S sequence for the 3’-PB domain. The 203 and 249 
mutations have been previously reported (11,15) , but 
the amino acid changes at these positions are different 
from our study and the previous unique study performed 
in Iran (23). The 203 mutation causes the replacement of 
aspartic acid by tyrosine (p.D203Y) while in Japanese 
patients with MCD, a change at nucleotide position 609 ( 
c.609C>A) causes the replacement of aspartic acid with 
glutamic acid at the same protein position (p.D203E)(11). 
In Iranian subjects, a change at nucleotid position leads to 
the replacement of histidine by ariginine at position 249 
of the protein (p.H249R) while in Indian patients with 
MCD, replacement of histidine by cysteine (p.H249C) 
has been reported (15).
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